Categories
| Category | |
|---|---|
| Health | 100% |
Explore sites in same category:
- myspondylitisteam.com Rank 1.4M. Estimated value 1,548$
- elisoler.com Rank 2M. Estimated value 1,056$
- pozvonochnik.info Rank 842.9K. Estimated value 2,556$
- docvita.com Rank 636.3K. Estimated value 3,396$
- arabaltmed.com Rank 1M. Estimated value 2,100$
- drbacsi.com Rank 3.2M. Estimated value 660$
- twedr.com Rank 210.3K. Estimated value 10,356$
- jlfisios.com Rank 1.2M. Estimated value 1,740$
- amansi.net Rank 3.2M. Estimated value 672$
- iadt.com Rank 0.9M. Estimated value 2,364$
Keyword Suggestion
Domain Informations
Takhzyro.com lookup results from whois.corporatedomains.com server:
- Domain created: 2017-12-20T21:46:47Z
- Domain updated: 2025-12-16T06:02:40Z
- Domain expires: 2026-12-20T21:46:47Z 0 Years, 339 Days left
- Website age: 8 Years, 25 Days
- Registrar Domain ID: 2202724572_DOMAIN_COM-VRSN
- Registrar Url: http://cscdbs.com
- Registrar WHOIS Server: whois.corporatedomains.com
- Registrar Abuse Contact Email: [email protected]
- Registrar Abuse Contact Phone: 8887802723
- Name server:
- NS-1041.AWSDNS-02.ORG
- NS-1583.AWSDNS-05.CO.UK
- NS-396.AWSDNS-49.COM
- NS-701.AWSDNS-23.NET
Network
- inetnum : 151.101.0.0 - 151.101.255.255
- name : SKYCA-3
- handle : NET-151-101-0-0-1
- status : Direct Allocation
- created : 2011-09-16
- changed : 2025-03-25
Owner
- organization : Fastly, Inc.
- handle : SKYCA-3
- address : Array,San Francisco,CA,94107,US
Abuse
- handle : ABUSE4771-ARIN
- name : Abuse Account
- phone : +1-415-496-9353
- email : [email protected]
Technical support
- handle : FRA19-ARIN
- name : Fastly RIR Administrator
- phone : +1-415-404-9374
- email : [email protected]
| Domain Provider | Number Of Domains |
|---|---|
| godaddy.com | 286730 |
| namecheap.com | 101387 |
| networksolutions.com | 69118 |
| tucows.com | 52617 |
| publicdomainregistry.com | 39120 |
| whois.godaddy.com | 32793 |
| enomdomains.com | 23825 |
| namesilo.com | 21429 |
| domains.google.com | 21384 |
| cloudflare.com | 20573 |
| gmo.jp | 18110 |
| name.com | 17601 |
| fastdomain.com | 14708 |
| register.com | 13495 |
| net.cn | 12481 |
| ionos.com | 12416 |
| ovh.com | 12416 |
| gandi.net | 12305 |
| registrar.amazon.com | 12111 |
Host Informations
- IP address: 151.101.3.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
Site Inspections
Port Scanner (IP: 151.101.3.10)
Spam Check (IP: 151.101.3.10)
Similar sites
Websites Listing
We found Websites Listing below when search with takhzyro.com on Search Engine
HAE Treatment: TAKHZYRO® (lanadelumab-flyo), Official …
In a 6.5-month clinical study of 125 people with HAE 12 years of age and older, TAKHZYRO significantly reduced the number of monthly attacks, compared with placebo. People taking TAKHZYRO also had fewer moderate or severe …
Takhzyro.comSign Up for More Info about TAKHZYRO® (lanadelumab …
Takeda reserves the right to rescind, revoke, or amend the Program without notice at any time. You can unsubscribe from either the Reminder Program or Informational Program by texting STOP to 36395. For questions about the Programs, text HELP to 36395 or visit bit.ly/2C4d01L. For questions about TAKHZYRO, please contact your physician.
Takhzyro.comTAKHZYRO | Homepage
Takeda Canada Inc. www.takeda.com/en-ca Bay Adelaide Centre 22 Adelaide Street West, Suite 3800 Toronto, ON M5H 4E3 Canada Tel: (647) 798‐2200 or 1 866‐397‐4473 ...
Takhzyro.caSign Up | TAKHZYRO® (lanadelumab-flyo)
This consent will be in effect until such time as you opt out of communications from Takeda. If, at any time, you no longer wish to receive communications from Takeda, you can opt out by calling 1-866-888-0660. Please see our privacy policy.
Takhzyro.comTAKHZYRO™ (lanadelumab injection) Now Approved
TAKHZYRO is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. 5. The recommended starting dose is 300 mg lanadelumab every 2 weeks. In patients who are stably attack free on treatment, a dose reduction of 300 mg lanadelumab every 4 weeks may be considered, especially in patients with low …
Int.takhzyro.comSign Up | TAKHZYRO™ (lanadelumab injection) HCP Website
TAKHZYRO (lanadelumab) Summary of Product Characteristics. November 2018. 6. Banerji A, Riedl MA, Bernstein JA, et al; for the HELP Investigators. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018;320(20):2108-2121. 7.
Int.takhzyro.comTAKHZYRO | Privacy Policy
Takeda Canada Inc. www.takeda.com/en-ca Bay Adelaide Centre 22 Adelaide Street West, Suite 3800 Toronto, ON M5H 4E3 Canada Tel: (647) 798‐2200 or 1 866‐397‐4473 ...
Takhzyro.caTAKHZYRO | Warnings and precautions
Takeda Canada Inc. www.takeda.com/en-ca Bay Adelaide Centre 22 Adelaide Street West, Suite 3800 Toronto, ON M5H 4E3 Canada Tel: (647) 798‐2200 or 1 866‐397‐4473 ...
Takhzyro.caTAKHZYRO | Side Effects
The most common side effect seen with TAKHZYRO ® was injection site reactions including pain, redness, and bruising; followed by: hypersensitivity, myalgia (muscle pain), dizziness and raised skin rash/skin redness. Do not drive or operate machinery if you feel dizzy after using TAKHZYRO ®.
Takhzyro.caTAKHZYRO (lanadelumab-flyo) | TAKHZYRO | HAE | US Site
2022-04-30 · If you are interested in ordering from Takeda's product offerings, please contact Customer Care at 1-800-423-2090 or email us at [email protected] If you already have a Takeda account, please contact your account representative.
Store.takeda.comTAKHZYRO (lanadelumab-flyo) injection - Home - Facebook
TAKHZYRO (lanadelumab-flyo) injection. 692 likes · 317 talking about this. TAKHZYRO® (lanadelumab-flyo) injection
Facebook.comTAKHZYRO® approved in Japan - HAE International (HAEi)
2022-03-29 · TAKHZYRO received its first approval for the prevention of HAE attacks in patients 12 years and older in 2018 in the United States and in the European Union and is now approved in more than 50 countries. TAKHZYRO is intended for self-administration or administration by a caregiver once trained by a healthcare professional. TAKHZYRO is supported by a robust …
Haei.orgTakhzyro Approved in Japan as Prophylactic for HAE Swelling …
2022-03-31 · Copy article link. Takhzyro (lanadelumab) has been approved in Japan to prevent acute swelling attacks in people, 12 and older, with hereditary angioedema (HAE). An estimated 2,000 to 3,000 people with HAE live in Japan, but fewer than 500 have been diagnosed due to a lack of awareness, according to Takeda, which markets the therapy.
Angioedemanews.comTakhzyro Boosts Life Quality in French Patients With Early Access
2022-04-07 · Takhzyro (lanadelumab) led to significant benefits for patients with hereditary angiodema (HAE) in France who received the therapy as part of an early-access program prior to its approval in Europe, a study has found. The treatment “reduced attack rates, improved quality of life, and was generally well tolerated,” the investigators wrote ...
Angioedemanews.comFDA approves new treatment for rare hereditary disease
Takhzyro is a plasma kallikrein inhibitor that is used to prevent swelling attacks from occurring. Takhzyro is a fully human IgG1 monoclonal antibody made in …
Fda.govTakhzyro - FDA prescribing information, side effects and uses
2022-02-01 · Takhzyro Description. Lanadelumab-flyo, a plasma kallikrein inhibitor, is a non-plasma derived, recombinant, fully human, monoclonal antibody (IgG1/κ-light chain) produced in Chinese Hamster Ovary (CHO) cells. Based on the amino acid sequence, the molecular weight of the non-glycosylated lanadelumab-flyo is 146 kDa.
Drugs.comTakhzyro: Dosage, side effects, alternatives, and more
2020-06-12 · Takhzyro (lanadelumab-flyo) is a prescription injection used to prevent hereditary angioedema attacks. Learn about dosage, side effects, alternatives, and more.
Medicalnewstoday.comHow to pronounce Takhzyro | HowToPronounce.com
2022-05-16 · Very easy. Easy. Moderate. Difficult. Very difficult. Thanks for your vote! Pronunciation of Takhzyro with 1 audio pronunciations. 1 rating.
Howtopronounce.comTakhzyro Found More Effective Than Cinryze at Preventing HAE …
2021-04-08 · Takhzyro and Cinryze are both approved first-line treatments marketed by Takeda for HAE. While Cinryze is administered intravenously (directly into the bloodstream) twice weekly to replenish C1-inhibitor levels, Takhzyro is an antibody that works by blocking the activity of kallikrein. Takhzyro is given by a subcutaneous (under-the-skin) injection.
Angioedemanews.comTakeda’s TAKHZYRO® (lanadelumab) Approved in Japan for …
2022-03-28 · TAKHZYRO received its first approval for the prevention of HAE attacks in patients 12 years and older in 2018 in the United States and in the European Union, and is now approved in more than 50 ...
Finance.yahoo.com
Domains Expiration Date Updated
| Site | Provider | Expiration Date |
|---|---|---|
| reevin.com | bigrock.com | 290 Days |
| acrysilcorporateinfo.com | publicdomainregistry.com | -3 Years, -201 Days |
| sms.frl | tucows.com | -3 Years, -180 Days |
| partcomap.com | name.com | -3 Years, -202 Days |
| fischerclinic.com | godaddy.com | -3 Years, -49 Days |
| andrisnelsons.com | networksolutions.com | -1 Years, -51 Days |
| by-wifi.com | nic.ru | -3 Years, -47 Days |
| beluminus.org | namecheap.com | -2 Years, -347 Days |
| extbel.com | hoster.by | -3 Years, -334 Days |
| globalit.com | godaddy.com | 3 Years, 113 Days |